Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig With Docetaxel vs Docetaxel in Metastatic Castration-resistant Prostate Cancer
2025-522713-29-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of pasritamig in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Radiographic progression-free survival (rPFS). Planned start Mar 2026; status: authorised.
02
Drugs
pasritamig
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2025-522713-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522713-29-00.